Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria.
about
17beta-Estradiol inhibits Ca2+-dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia.17β-Estradiol inhibits phosphorylation of stromal interaction molecule 1 (STIM1) protein: implication for store-operated calcium entry and chronic lung diseases.Exacerbations in cystic fibrosis: 2 . prevention.Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosisEffects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis.Estrogen aggravates inflammation in Pseudomonas aeruginosa pneumonia in cystic fibrosis mice.Determining the influence of environmental and patient specific factors on the polymicrobial communities of the cystic fibrosis airway.Non-genomic estrogen regulation of ion transport and airway surface liquid dynamics in cystic fibrosis bronchial epithelium.Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load?Higher mobility scores in patients with cystic fibrosis are associated with better lung function.Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical responseScreening for symptoms of depression and anxiety in adolescents and young adults with cystic fibrosisSerum Iron Level Is Associated with Time to Antibiotics in Cystic FibrosisIV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosisAccurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence".C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations.Putting lung function and physiology into perspective: cystic fibrosis in adults.Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice.Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.Low-level resistance and clonal diversity of Pseudomonas aeruginosa among chronically colonized cystic fibrosis patients.Early detection of pulmonary exacerbations in children with Cystic Fibrosis by electronic home monitoring of symptoms and lung function.17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor.A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis.Physiological markers of exercise capacity and lung disease severity in cystic fibrosis.Rescue therapy within the UK Cystic Fibrosis Registry: An exploration of predictors of intravenous antibiotic use amongst adults with CF.Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry.Life-space mobility is associated with frequency of hospitalization in adults with cystic fibrosis.
P2860
Q22306299-F9950628-DE91-458C-A4C1-805B575D7D5CQ30409431-D0F759EC-8467-48A1-AF1D-30A582F3DB97Q30480308-BA090C1C-AAB5-401E-AC65-3E2D77DB1735Q33874056-0D014BFE-17C6-431B-B4AA-589AA9A8D4D8Q34118468-91A86FEC-F41A-4397-AB71-5E0DFEB15939Q34426614-125F6B96-1E7D-4D0E-B752-FDF5B9915644Q34488114-C76C8535-F715-46E6-A46F-C8DFD758BD3CQ35040980-90F42DCB-E900-4E6B-8D32-D3E7437775BAQ35060166-850AEA97-D3FA-4707-B725-988164801CADQ35144062-0AEC3D9C-E6CD-442B-A21A-2C18AA665DC4Q35358667-2522C919-EBFE-4099-A30D-EBF90D930DD7Q36292558-98028B91-34F5-4DD2-A6E5-33C1382D0C68Q36437025-E3A4165A-3F21-4667-B4D1-23E96CE1BD7EQ36827488-6B02BB1A-5785-4672-AC4D-560A346251BBQ36944153-20EF55CF-25E4-4569-AFC7-BFA8077A9775Q37568497-F8A79EA1-7EE9-417A-9591-82A251DB5A50Q38248996-C247E006-B2FF-47BC-9C73-4FAC47A5D47DQ38360133-B5220BCE-9F01-45A7-AF53-4DDEB15C1D5EQ38543069-1A41CB1B-DA4D-47F5-ADD1-84C1C6F4C65CQ40226374-8C195821-FBBF-40EA-BD6D-8D5B9275BCFDQ40927845-017F391F-BC23-4B82-B34B-AAECCFF2E4AEQ42011378-3882D1A4-E7C5-4C03-8812-03B174DE7C68Q43105666-8C607E21-5186-4381-8FE1-38DAA8D2C50CQ44016904-DFA1606B-0EA6-41AB-B9E4-483757FB3AB6Q44948545-AF0837B7-1BE3-4C60-8259-3F1D1AB77DBEQ47381971-EA154A5A-55CE-4B3E-9D2C-A9E264262AA1Q47949888-9D23C5D3-6337-4C01-8498-F665E15E21EDQ51649472-137EC7C6-4DCE-452A-90B6-3004C41C307DQ53029501-6FD232D2-21B3-43C4-B15C-B7DA5898A712
P2860
Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Predictors of pulmonary exacer ...... with multi-resistant bacteria.
@ast
Predictors of pulmonary exacer ...... with multi-resistant bacteria.
@en
type
label
Predictors of pulmonary exacer ...... with multi-resistant bacteria.
@ast
Predictors of pulmonary exacer ...... with multi-resistant bacteria.
@en
prefLabel
Predictors of pulmonary exacer ...... with multi-resistant bacteria.
@ast
Predictors of pulmonary exacer ...... with multi-resistant bacteria.
@en
P2093
P2860
P50
P356
P1433
P1476
Predictors of pulmonary exacer ...... with multi-resistant bacteria
@en
P2093
K L Vandemheen
M Noseworthy
N Paterson
P2860
P304
P356
10.1136/THX.2006.061366
P407
P577
2006-07-14T00:00:00Z